These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20058009)

  • 1. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
    Scatena CD; Kumer JL; Arbitrario JP; Howlett AR; Hawtin RE; Fox JA; Silverman JA
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):881-8. PubMed ID: 20058009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
    Walsby EJ; Coles SJ; Knapper S; Burnett AK
    Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
    Hawtin RE; Stockett DE; Byl JA; McDowell RS; Nguyen T; Arkin MR; Conroy A; Yang W; Osheroff N; Fox JA
    PLoS One; 2010 Apr; 5(4):e10186. PubMed ID: 20419121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.
    Jasek-Gajda E; Jurkowska H; Jasińska M; Litwin JA; Lis GJ
    Apoptosis; 2019 Dec; 24(11-12):849-861. PubMed ID: 31482470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells.
    Jasek-Gajda E; Gajda M; Jasińska M; Litwin JA; Lis GJ
    Anticancer Res; 2018 Nov; 38(11):6147-6156. PubMed ID: 30396931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
    Nandy P; Periclou AP; Avramis VI
    Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
    Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
    Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
    Hotinski AK; Lewis ID; Ross DM
    Expert Opin Pharmacother; 2015 Jun; 16(9):1395-402. PubMed ID: 25958926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
    Goto S; Goto H; Yokosuka T
    Int J Hematol; 2016 May; 103(5):572-83. PubMed ID: 26886449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
    Jamieson GC; Fox JA; Poi M; Strickland SA
    Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
    Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
    Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
    Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
    Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.
    Akutsu M; Furukawa Y; Tsunoda S; Izumi T; Ohmine K; Kano Y
    Leukemia; 2002 Sep; 16(9):1808-17. PubMed ID: 12200697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia.
    Mino T; Ureshino H; Ueshima T; Kashimoto N; Yamaguchi T; Naka K; Inaba T; Ichinohe T
    Invest New Drugs; 2023 Oct; 41(5):751-760. PubMed ID: 37702844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
    Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
    Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.